Definium Therapeutics Gears Up for Investor and Analyst Day in New York
1. Key Event Announced for April 22, 2026
Definium Therapeutics Inc. (NASDAQ: DFTX), a promising late-stage clinical biopharmaceutical company, has announced details for its highly anticipated Investor and Analyst Day, set to take place in New York City on April 22, 2026. This event aims to shed light on Definium's innovative therapeutic approaches to combat psychiatric and neurological disorders, with a focus on its lead investigational program, DT120 ODT (lysergide tartrate).
2. Focus on Mental Health Innovations
The event will feature presentations and interactive sessions led by Definium’s executive leadership team alongside distinguished external key opinion leaders. These experts will delve into the evolving treatment landscape for generalized anxiety disorder (GAD) and major depressive disorder (MDD), two significant mental health challenges affecting millions worldwide.
Key Topics of Discussion
Among the pivotal topics to be addressed during the sessions are:
- DT120 ODT Development: An overview of Definium’s lead program currently in Phase 3 development, aimed at treating GAD and MDD.
- Anticipated Data Readouts: Expectations concerning the topline data readouts anticipated in 2026, which could significantly influence investor sentiment and stock performance.
- Market Opportunities: Insights into the potential market landscape for DT120 ODT, highlighting the business implications of successful clinical outcomes.
3. Notable Key Opinion Leaders
The event will feature an impressive lineup of key opinion leaders, renowned for their expertise in psychiatry and mental health:
- Brittany Albright, MD, MPH, DABOM: Owner & CEO of Sweetgrass Psychiatry and Affiliate Assistant Professor at the Medical University of South Carolina.
- Andrew Penn, MS, PMHNP: Professor at the University of California, San Francisco School of Nursing and Director of Clinical Nursing Operations at Salma Health.
- Shannon Sarkar, PhD, LPC, NCC: Licensed Professional Counselor and Adjunct Professor of Counselor Education, recognized for her work in psychedelic-assisted therapy.
4. Event Logistics
Date and Venue
- Date: Wednesday, April 22, 2026
- Time: 10 AM – 12 PM EDT (followed by lunch)
- Location: Well& by Durst, 151 W 42nd St, New York, NY 10036
Registration Details
In-person attendance is limited to invited research analysts and institutional investors, although all interested parties can access the event virtually. Participants can register through the provided registration link, which will also facilitate viewing the live or archived webcast on Definium's Investor Relations website. The archived version will be available for at least 30 days post-event, ensuring broad access to the information shared.
5. Definium's Mission
Definium Therapeutics is dedicated to pioneering a new era in psychiatry by leveraging scientific advancements in psychedelics. With a mission to create accessible treatments that address the root causes of psychiatric and neurological disorders, the company aspires to significantly impact the mental health care landscape. By focusing on evidence-based solutions, Definium aims to reshape the future of mental health treatment and provide meaningful relief to those affected by these conditions.
For more information about Definium Therapeutics and its innovative projects, visit their official website and follow them on social media platforms including Instagram, LinkedIn, and X.
As anticipation builds for the upcoming Investor and Analyst Day, stakeholders will be keenly observing Definium's progress in transforming mental health treatment and the potential implications for its stock performance in the coming months.
